Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals Print E-mail
  
Thursday, 19 March 2009 07:05
Antibodies to conserved epitopes on the human immunodeficiency virus (HIV) surface protein gp140 can protect against infection in non-human primates, and some infected individuals show high titres of broadly neutralizing immunoglobulin (Ig)G antibodies in their serum. However, little is known about the specificity and activity of these antibodies1, 2, 3. To characterize the memory antibody responses to HIV, we cloned 502 antibodies from HIV envelope-binding memory B cells from six HIV-infected patients with broadly neutralizing antibodies and low to intermediate viral loads. We show that in these patients, the B-cell memory response to gp140 is composed of up to 50 independent clones expressing high affinity neutralizing antibodies to the gp120 variable loops, the CD4-binding site, the co-receptor-binding site, and to a new neutralizing epitope that is in the same region of gp120 as the CD4-binding site. Thus, the IgG memory B-cell compartment in the selected group of patients with broad serum neutralizing activity to HIV is comprised of multiple clonal responses with neutralizing activity directed against several epitopes on gp120.
Correspondence to: This e-mail address is being protected from spambots. You need JavaScript enabled to view it 1,5 Correspondence and requests for materials should be addressed to M.C.N.

Link: http://www.nature.com/nature/journal/vaop/ncurrent/abs/nature07930.html

Johannes F. Scheid1,6, Hugo Mouquet1, Niklas Feldhahn1, Michael S. Seaman7, Klara Velinzon1, John Pietzsch1,8, Rene G. Ott2, Robert M. Anthony2, Henry Zebroski3, Arlene Hurley4, Adhuna Phogat9, Bimal Chakrabarti9, Yuxing Li9, Mark Connors10, Florencia Pereyra11, Bruce D. Walker11, Hedda Wardemann12, David Ho13, Richard T. Wyatt9, John R. Mascola9, Jeffrey V. Ravetch2 & Michel C. Nussenzweig1,5

  1. Laboratory of Molecular Immunology,
  2. Laboratory of Molecular Genetics and Immunology,
  3. Proteomics Resource Center,
  4. Rockefeller University Hospital, and,
  5. Howard Hughes Medical Institute, The Rockefeller University, New York, New York 10065, USA
  6. Charite Universitaetsmedizin, D-10117 Berlin, Germany
  7. Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
  8. Institute of Chemistry and Biochemistry, Freie Universität Berlin, D-14195 Berlin, Germany
  9. Vaccine Research Center, and,
  10. Laboratory of Immunoregulation, National Institutes of Allergy and Infectious Diseases, National Institutes of Health Bethesda, Maryland 20892, USA
  11. Partners AIDS Research Center, Mass General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
  12. Max Planck Institute for Infection Biology, D-10117 Berlin, Germany
  13. Aaron Diamond Aids Research Center; New York, New York 10065, USA
Del.icio.us     Digg This!     Facebook     Google     Reddit     Stumble It!
Last Updated ( Thursday, 19 March 2009 07:41 )
 

Please Donate!

Please make a tax deductible donation to Zephyr LTNP Foundation, a 501(c)(3) entity via Paypal. No Paypal account required.
 

CROI 2011

  • Wednesday 9th March 2011
    This is our final bulletin from CROI 2011. We hope you have found our news coverage useful. You can find all our coverage at www.aidsmap.com/croi2011, including the news reports and bulletins.We are always looking for ways of improving and developing our resources – so if you have any comments that you would like
  • Thursday 3rd March 2011
    There is increasing evidence of the transmission of HIV strains with resistance to anti-HIV drugs in low- and middle-income countries. Research in eleven sub-Saharan African countries showed that the chances of detecting transmitted resistance increased by over a third each year that a country had been scaling up HIV treatment. A separate study involving people recently diagnosed
  • Wednesday 2nd March 2011
    A new type of anti-HIV drug that targets the first step in HIV’s entry into cells has done well in a Phase IIa study. Currently known as BMS-663068, the drug was shown to be safe and to work against the virus. HIV cell entry is a three-step process. The virus must first attach to the

Follow Us

  • Facebook Page: zephyrfoundation.org
  • Twitter: zephyrfound
  • YouTube: zephyrfoundation

Controllers in Study

 Donation Thermometer
 Donation Thermometer
 Donation Thermometer
86%

Our Goal:
2000
Currently:
1725
Updated:
December 30, 2009

Current Breakdown: 505 Elite Controllers 1009 Viremic Controllers 211 Other